PharmAust ASX:PAA) is a clinical-stage biotechnology company developing therapeutics for neurodegenerative diseases. The company is focused on repurposing monepantel for amyotrophic lateral sclerosis, the most common form of motor neurone disease. It has recently realised significant milestones in the development of monepantel for this sclerosis. These achievements include a recent study that could potentially lead to accelerated approval with the US FDA for monepantel for the treatment of amyotrophic lateral sclerosis in 2026. Joining The Stock Network’s Lel Smits ahead of appearing at Australian Equities Day in Singapore is PharmAust Managing Director Dr Michael Thurn.
1. A re-prioritised commercialisation strategy
PharmAust has recently moved to deliberately prioritise neurodegenerative diseases, including Alzheimer’s, Parkinson’s and Huntington’s disease. What motivated this shift in focus?
2. Monepantel gets US FDA Orphan Drug Designation for treatment of ALS
PharmAust’s Monepantel was recently granted Orphan Drug Designation for the treatment of ALS by the US FDA. What positives do you expect to flow from this development?
_ _ _
Subscribe to TSN’s YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1
_ _ _
Follow TSN for the latest stock news and interviews:
Twitter: https://twitter.com/thestocknet
Instagram: https://www.instagram.com/thestocknetwork/
LinkedIn: https://www.linkedin.com/company/the-stock-network/
TikTok: https://www.tiktok.com/@thestocknet?lang=en
Facebook: https://www.facebook.com/TheStockNet/
_ _ _
Connect with our host Lel Smits online – @LelSmits
– Twitter / X: https://twitter.com/lelsmits
– Instagram: https://www.instagram.com/lelsmits/
– LinkedIn: https://www.linkedin.com/in/leldesmits/
– TikTok: https://www.tiktok.com/@lelsmits?lang=en
– Facebook: https://m.facebook.com/lelsmits/
– Threads: https://www.threads.net/@lelsmits
_ _ _
Disclaimer
The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss.
This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer.
_ _ _
Visit TSN’s website to sign up for regular stock updates: http://www.thestocknetwork.com.au
_ _ _